On Wednesday, Vincerx Pharma Inc (VINC) stock saw a decline, ending the day at $1.56 which represents a decrease of $-0.09 or -5.45% from the prior close of $1.65. The stock opened at $1.97 and ...
SAN MATEO, Calif. - Vincerx Pharma, Inc. (NASDAQ:VINC), a clinical-stage biopharmaceutical company with a current market capitalization of $2.77 million, and Oqory, Inc. announced promising results ...
Companies also provide insights into proposed strategic mergerSAN MATEO, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Vincerx ...
The company has already cut its workforce, seen a leadership change and agreed to be acquired. Here's what's next.
Vincerx’s Common Stock to Begin Trading on a Split-adjusted Basis on January 28, 2025SAN MATEO, Calif., Jan. 23, 2025 (GLOBE ...
In terms of valuation, Vincerx Pharma Inc’s market capitalization stands at $3.62 million. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market ...
Vincerx Pharma (VINC) announced that its board of directors approved a 1-for-20 reverse stock split of its issued shares of common stock, which ...
Vincerx Pharma, Inc. (NASDAQ:VINC), a pharmaceutical company, announced today an agreement with H.C. Wainwright & Co., LLC to sell up to $30 million of its common stock in an at-the-market equity ...
EST Vincerx Pharma (VINC) files $100M mixed securities shelfInvest with Confidence: Follow TipRanks' Top Wall Street Analysts to uncover ...
Vincerx Pharma, Inc. has announced a proposed merger with Oqory, Inc., a clinical-stage company developing antibody-drug conjugates (ADCs) for various cancer types. After the merger, Oqory's ...
Vincerx Pharma, Inc. operates as a clinical-stage biopharmaceutical company which develops antibody drugs. It focuses on leveraging its extensive development and oncology expertise to advance new ...
Vincerx Pharma said it had agreed to merge with private biotechnology company Oqory after a review of strategic alternatives. The biotech company said that it would also implement cost-cutting ...